CPRX Catalyst Pharmaceuticals Inc

USD 15.89 -0.39 (-2.37%)
Icon

Catalyst Pharmaceuticals Inc (CPRX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Hold

Average User
Rating

USD 16.27

+0.52 (+3.30)%

USD 1.96B

1.47M

USD 28.71(+76.49%)

USD 20.00 (+22.93%)

Icon

CPRX

Catalyst Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 15.89
-0.39 (-2.37%)
As of 03:21PM EDT.
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Hold

Average User
Rating

USD 1.96B

USD 20.00 (+22.93%)

USD 16.27

Catalyst Pharmaceuticals Inc (CPRX) Stock Forecast

Show ratings and price targets of :
USD 28.71
(+76.49%)

Based on the Catalyst Pharmaceuticals Inc stock forecast from 5 analysts, the average analyst target price for Catalyst Pharmaceuticals Inc is USD 28.71 over the next 12 months. Catalyst Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Catalyst Pharmaceuticals Inc is Slightly Bullish , which is based on 10 positive signals and 5 negative signals. At the last closing, Catalyst Pharmaceuticals Inc’s stock price was USD 16.27. Catalyst Pharmaceuticals Inc’s stock price has changed by -3.78% over the past week, +13.38% over the past month and -0.61% over the last year.

No recent analyst target price found for Catalyst Pharmaceuticals Inc
No recent average analyst rating found for Catalyst Pharmaceuticals Inc

Company Overview Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phospha...Read More

355 Alhambra Circle, Coral Gables, FL, United States, 33134

167

December

USD

USA

Adjusted Closing Price for Catalyst Pharmaceuticals Inc (CPRX)

Loading...

Unadjusted Closing Price for Catalyst Pharmaceuticals Inc (CPRX)

Loading...

Share Trading Volume for Catalyst Pharmaceuticals Inc Shares

Loading...

Compare Performance of Catalyst Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CPRX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Catalyst Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -1.14 (-0.27%) USD107.38B 29.93 21.06

ETFs Containing CPRX

Symbol Name CPRX's Weight Expense Ratio Price(Change) Market Cap
XSGI:SW
Xtrackers S&P Global Infr.. 3.92 % 0.60 % +0.22 (+0.45%) USD0.22B

Frequently Asked Questions About Catalyst Pharmaceuticals Inc (CPRX) Stock

Based on ratings from 5 analysts Catalyst Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 7 buy, sell and hold ratings.

Unfortunately we do not have enough data on CPRX's stock to indicate if its a good dividend stock.

Based on targets from 5 analysts, the average taret price for CPRX is USD 28.71 over the next 12 months. The maximum analyst target price is USD 34 while the minimum anlayst target price is USD 23.

CPRX stock's Price/Earning ratio is 26.38. Our analysis grades CPRX stock's Price / Earning ratio at F. This means that CPRX stock's Price/Earning ratio is above 78% of the stocks in the Biotechnology sector in the NSD exchange. Based on this CPRX may be a overvalued for its sector.

The last closing price of CPRX's stock was USD 16.27.

The most recent market capitalization for CPRX is USD 1.96B.

Based on targets from 5 analysts, the average taret price for CPRX is projected at USD 28.71 over the next 12 months. This means that CPRX's stock price may go up by +76.49% over the next 12 months.

Following are ETFs with the highest allocation to Catalyst Pharmaceuticals Inc's stock :

XSGI:SW

As per our most recent records Catalyst Pharmaceuticals Inc has 167 Employees.

Catalyst Pharmaceuticals Inc's registered address is 355 Alhambra Circle, Coral Gables, FL, United States, 33134. You can get more information about it from Catalyst Pharmaceuticals Inc's website at https://www.catalystpharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...